Laurus Labs inks pact with Global FundDate: 27 March 2019 Tags: Biotechnology
Drug maker Laurus Labs has entered into strategic partnership agreement with The Global Fund to Fight AIDS, Tuberculosis and Malaria. It is three-and-a-half-year pact that will fetch company volume commitments from fund for treatment of HIV/AIDS.
Under this pact, Laurus Labs has also received and executed order for the Global Fund in February 2019 that involved supplies of its fixed dose combination (FDC) drug Tenofovir/Lamivudine/Dolutegravir (TLD) to high disease-burden countries in sub Saharan African region.
Global Fund to Fight AIDS, Tuberculosis and Malaria
- It is international financing organization that aims to attract, leverage and invest additional resources to end epidemics of HIV/AIDS, TB and malaria to support attainment of SDG established by UN.
- It is public-private partnership organization i.e. operates in partnership model between governments, civil society, private sector and people to accelerate end of three diseases.
- It is world's largest financier of AIDS, TB, and malaria prevention, treatment, and care programs. It was started in January 2002. It maintains its secretariat in Geneva, Switzerland.
- It is financing mechanism rather than an implementing agency. Programs are implemented by in-country partners such as ministries of health, while Global Fund secretariat monitoring programs.